Mark Litton
Vermögen: 550 426 $ am 30.06.2026
Vermögen: 550 426 $ am 30.06.2026
Mark J.
Litton was the founder of Lundbeck Seattle BioPharmaceuticals, Inc., founded in 2004, where the titles held included Secretary, Treasurer & Chief Business Officer from 2014 to 2018.
Current jobs include President, Chief Executive Officer & Director at LeonaBio, Inc. since 2021, and Director at Lumen Bioscience, Inc. Former jobs include Manager-Business Development at Sirna Therapeutics, Inc. from 1997 to 1999; Vice President-Business Development at Celltech Group Plc from 1999 to 2004; Vice President-Business Development at Chiroscience Group Plc; Research Associate at DNAX Research, Inc. from 1991 to 1994; and President & Chief Operating Officer at Alpine Immune Sciences, Inc. from 2018 to 2019.
Education history includes an MBA from Santa Clara University in 1994, an undergraduate degree from the University of California, Santa Cruz in 1990, and a doctorate from the University of Stockholm in 1997.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LEONABIO, INC. 0.64% | 01.05.2026 | 59’894 ( 0.64% ) | 550 426 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LEONABIO, INC. | Vorstandsvorsitzender | 16.06.2021 |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. BiotechnologyHealth Technology Develops biologic drug platform | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Präsident | 16.04.2019 |
| ALDER BIOPHARMACEUTICALS, INC. | Gründer | 01.08.2018 |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Develops and manufactures pharmaceuticals | Corporate Officer/Principal | 01.01.2004 |
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides and develops pharmaceutical products | Corporate Officer/Principal | 01.01.1999 |
DNAX Research, Inc. | Corporate Officer/Principal | 01.01.1994 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Provides and develops pharmaceutical products | Commercial Services |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
LeonaBio, Inc.
LeonaBio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Chiroscience Group Plc
Chiroscience Group Plc Miscellaneous Commercial ServicesCommercial Services Research based pharmaceutical group | Commercial Services |
Santa Clara University
Santa Clara University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Santa Cruz
University of California, Santa Cruz Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Stockholm
University of Stockholm Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
DNAX Research, Inc. | |
Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as an bio pharmaceutical company that develops immunotherapies for autoimmune and inflammatory diseases | Health Technology |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. BiotechnologyHealth Technology Develops biologic drug platform | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen